#Pembrolizumab is an active hashtag on Bluesky. In the last 30 days, 6 people shared 19 posts with it — around 1 a day. Activity is down 87% versus the previous week, peaking on Aug 26 with 6 posts.
oncodaily.com
NFCR joins the nation in mourning the passing of former President James (Jimmy) Carter - OncoDaily
NFCR joins the nation in mourning the passing of former President James (Jimmy) Carter / cancer, Melanoma, National Foundation for Cancer Research, NFCR,
oncodaily.com
Five articles suggested by Yüksel Ürün - OncoDaily
Five articles suggested by Yüksel Ürün / Ankara University School of Medicine, BRCA, cancer, Charlie A. Hamm, CLEAR, Elizabeth J.Schafer, fight against
oncodaily.com
Interesting results from the exploratory biomarker analysis of KN-522 study - OncoDaily
Interesting results from the exploratory biomarker analysis of KN-522 study / Amol Akhade, biomarkers, cancer, Heidi Ko, metabolic pathway, Molecular
clinicaltrials.gov
ClinicalTrials.gov
oncodaily.com
KEYTRUDA-Chemotherapy Approved by NICE for Advanced Endometrial Cancer in England - OncoDaily
NICE approves KEYTRUDA-chemotherapy combo as first-line therapy for advanced endometrial cancer, including pMMR tumors, based on KEYNOTE-868 trial data.
oncodaily.com
CUE-101 and Pembrolizumab Show Promising Results in HPV-Positive Head and Neck Cancer - OncoDaily
CUE-101 with pembrolizumab shows 50% response and 32-month OS in HPV-positive HNSCC. A novel T-cell therapy with strong early-phase clinical promise.
oncodaily.com
ESMO GI 2025 Highlights: BXCL701 + Pembrolizumab in PDAC
ESMO GI 2025 highlights: EXPEL PANC Phase II trial shows promising results for BXCL701 + pembrolizumab in second-line advanced PDAC.
oncodaily.com
KEYNOTE-991. Pembrolizumab Fails to Improve OS in mHSPC
KEYNOTE-991 trial shows no survival benefit from adding pembrolizumab to enzalutamide and ADT in mHSPC.
oncodaily.com
Immunotherapy Helps Extend the Lives of Patients with Rare Form of Skin Cancer - OncoDaily
Immunotherapy Helps Extend the Lives of Patients with Rare Form of Skin Cancer / Agustin Vega-Crespo, Alexandra Ikeguchi, Andrew S. Brohl, Antoni Ribas, Boban
oncodaily.com
10-Minute Immunotherapy Infusion: Safe, Efficient Delivery of Nivolumab and Pembrolizumab - OncoDaily
Explore how docus-based 10-minute immunotherapy infusion with nivolumab/pembrolizumab boosts efficiency without compromising safety in oncology care.
oncodaily.com
Sacituzumab Govitecan + Pembrolizumab in mNSCLC
Sacituzumab govitecan combined with pembrolizumab shows promising efficacy and manageable safety in first-line metastatic NSCLC.
third-news.com
Promising Survival Results for Ivonescimab Over Pembrolizumab in NSCLC Treatment at WCLC 2026
At the WCLC 2026, Akeso presented positive overall survival results for Ivonescimab in first-line treatment of advanced NSCLC compared to Pembrolizumab.
third-news.com
Latest Findings on Sacituzumab Govitecan and Pembrolizumab in Treating NSCLC Fail to Show Significant Progress
Recent research reveals that Sacituzumab govitecan combined with pembrolizumab did not provide significant survival advantages for NSCLC patients, despite longer progression-free survival.
third-news.com
Significant Survival Advantage of Ivonescimab Over Pembrolizumab in NSCLC: HARMONi-2 Study Insights
The HARMONi-2 study reveals promising overall survival benefits of ivonescimab compared to pembrolizumab in advanced NSCLC patients, marking a potential new standard in treatment.
third-news.com
Groundbreaking Approval for Lifesaving Treatment in Europe for TNBC Patients
The European Commission approves a groundbreaking combination therapy for triple-negative breast cancer, marking a significant advancement in treatment options for patients.
gutepillen-schlechtepillen.de
Mit dem Krebsmedikament Pembrolizumab werden enorme Gewinne erzielt - Gute Pillen - Schlechte Pillen
Forschungskosten dienen der Rechtfertigung hoher Arzneimittelpreise. Die NGO Public Eye hat ausgerechnet, dass das gar nicht stimmt.
third-news.com
Ivonescimab Shows Promise in Improving Survival for NSCLC Patients Over Pembrolizumab
A recent phase III trial shows ivonescimab significantly improves overall survival for NSCLC patients, outperforming pembrolizumab. Clinical implications are significant.
www.dermatologyadvisor.com
INTerpath-001: Adjuvant Intismeran + Pembrolizumab Boosts RFS in Melanoma
Topline phase 3 INTerpath-001 trial results show adjuvant intismeran autogene plus pembrolizumab significantly improves RFS and DMFS in resected stage IIB-IV melanoma.
www.cancerresearchuk.org
Pembrolizumab (Keytruda)
Pembrolizumab is a type of immunotherapy. You might have it for a number of different types of cancers.
clinicaltrials.gov
ClinicalTrials.gov
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.